Navigation Links
Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
Date:7/12/2010

erson">Rogelio Braceras, M.D., senior medical director, thrombosis at Daiichi Sankyo, Inc.  "In fact, a recent Clinical Alert from the American College of Cardiology Foundation and American Heart Association noted that several ongoing studies are being conducted to evaluate whether directly measuring the antiplatelet effect might be useful to help tailor antiplatelet therapy for patients."

This collaborative program will work to provide healthcare professionals information about the factors that affect response to antiplatelet medication and how platelet function testing works.  Platelet function testing can be measured at the point of care and provides quick insight to physicians about the antiplatelet effect of a specific medicine.  With this information, physicians can make more informed treatment decisions.

"By using platelet function testing, physicians now have another tool to help them manage their patients on antiplatelet therapy," said Tiffany Olson, vice president of Diagnostics, Eli Lilly and Company.  

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors, and GP IIb/IIIa inhibitors, the VerifyNow System is widely used in various clinical settings where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events suc
'/>"/>

SOURCE Accumetrics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Accumetrics, Inc. Announces GRAVITAS Trial 50 Percent Enrolled
2. Novocell Becomes ViaCyte, Inc., as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes
3. ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes
4. Patient Safety Technologies, Inc., Contracts to Implement the Safety-Sponge(TM) System at The Mount Sinai Hospital in New York
5. OMNIlife science, Inc., Announces U.S. Distribution Agreement with SERF-Dedienne Sante of France for its ION free Large Diameter Head Dual Mobility Acetabular Cup System
6. NeoMatrix, Inc., Awarded New Technology Agreement by Novation for HALO(R) Breast Pap Test
7. Dr. Yahia Gawad, CEO of CardioGenics Holdings, Inc., Interviewed in MedTech Executive
8. Sanofi-aventis to Acquire Chattem Inc., Creating a Strong U.S. Consumer Healthcare Platform
9. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
10. Nyer Medical Group, Inc., Announces Agreements to Sell Certain Eaton Apothecary Assets to Walgreens and Sell Operating Subsidiarys Stock to Investors
11. BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Reportlinker.com announces that ... its catalogue: Acute Heart Failure Global ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute Heart Failure ... Summary GlobalData,s clinical trial report, "Acute Heart ... data on the Acute Heart Failure clinical trial ...
(Date:9/2/2014)... 2, 2014    - ... muestran agentes antitrombóticos no utilizados óptimamente para prevenir ... Las presentaciones de GARFIELD-AF en el ESC CONGRESS ... los resultados de pacientes en riesgo de sufrir ... Los datos de casi 12.500 pacientes ...
(Date:9/2/2014)... , -- GARFIELD-AF ... into treatment and outcomes of patients at risk ... Data from nearly 12,500 patients enrolled ... Fibrillation (GARFIELD-AF), an innovative, independent academic research initiative, ... fibrillation (AF) patients remain sub-optimal despite the transition ...
Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... Solutions Development Company (MSDC), a drug discovery and ... metabolic diseases, announced today that it has launched ... second drug candidate for the treatment of type ... placebo-controlled clinical trial will involve approximately 125 patients ...
... SAN and NYSE: SNY ) announced today ... Rights (CVRs) offered to Genzyme shareholders as part of ... by the U.S. Securities and Exchange Commission. ... Genzyme, sanofi-aventis has commenced an exchange offer to acquire ...
Cached Medicine Technology:Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 3
(Date:9/2/2014)... -- Complications are rare among breast cancer patients ... indicates. However, the researchers did find that ... higher risk for certain complications than a single ... breast cancer patients who had a single (64 ... and were followed for 30 days after surgery. ...
(Date:9/2/2014)... their own spread throughout the body by coaxing cells ... to a new report by Johns Hopkins scientists. , ... Communications , the researchers describe animal and cell-culture experiments ... by breast cancer cells. These molecules cause lymphatic endothelial ... produce proteins called CCL5 and VEGF. CCL5 attracts tumor ...
(Date:9/2/2014)... (PRWEB) September 03, 2014 Operators in ... to millions of people annually, arranging care and counsel ... and private enterprises are expected to derive $39.4 billion ... donations and private income. Over the five years through ... annualised rate of 6.6%, including growth of 4.1% in ...
(Date:9/2/2014)... 2, 2014 (HealthDay News) -- Melatonin supplements did not ... fractures, a new study found. Many older hospital ... due to disruption of their normal sleep-wake cycle. A ... that contributes to delirium, but there has been little ... This study included 378 patients, average age 84, ...
(Date:9/2/2014)... Steven Reinberg HealthDay Reporter ... the Ebola outbreak continues to overwhelm health-care workers in ... States and the United Nations called on Tuesday for ... of the often-fatal virus. Dr. Thomas Frieden, director ... said that without a greater global commitment in resources ...
Breaking Medicine News(10 mins):Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:‘Prepped’ by tumor cells, lymphatic cells encourage breast cancer cells to spread 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Community Services in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:More Global Help Needed to Fight Ebola Outbreak 2Health News:More Global Help Needed to Fight Ebola Outbreak 3
... screening program to detect peripheral arterial disease (PAD) on time ... For Life? this program can help detect the onset of ... of having an amputation by half. // ... affects every vascular bed in the body and it increases ...
... has the remarkable ability to discriminate between self and ... immune system, the human body would have lost its ... // ,The immune system produces certain substances ... cells, effectively labeling them as "bad" so that other ...
... Baptist Medical Center certain herbs and dietary supplements can ... other gastrointestinal problems.// ,The researcher Kemper, had ... were out there doing, and came up with a ... historically, 50 years ago, people used home remedies. Then ...
... unusual antibiotics that have the potential to be effective ... at the 230th national meeting of the American Chemical ... ,The new antibiotics are synthetic forms of cephalosporin, a ... kill bacteria by masquerading as components of the bacterial ...
... a research team led by the National Human Genome ... experimental anti-cancer drugs also shows promise in laboratory studies ... aging. // ,These drugs belong to a ... tested in people with myeloid leukemia, neurofibromatosis and other ...
... loss of interest in eating during old age is the ... a plan which will help older people eat nutritious food ... ,Doctors at the institute advise that High fibre in ... can help fight diabetes, heart disease and diverticulosis. Folic acid ...
Cached Medicine News:Health News:Diabetic Amputation May Reduce If Free Screenings Are There 2Health News:Fighting against disease as easy as eating eggs 2Health News:Atypical Antibiotics For Super Bugs 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: